Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that parents/Legally Acceptable Representatives (LARs) can and will comply with the requirements of the protocol.~* Children, male or female between, and including, 6 and 35 months of age at the time of first study vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Healthy children as established by medical history and clinical examination before entering the study.~* Parent/LAR access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.~* Subjects who are likely to reside in the vicinity of the study centre for the duration of the study. In studies using the home-based model for vaccination and follow-up, subjects who are likely to remain in the vicinity of the area where they were recruited.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration of any vaccine 30 days prior and 21 days after any study vaccine administration.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines such as egg protein or thiomersal.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of any neurological disorders or seizures.~* Acute disease at the time of enrolment.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory tests.~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned administration during the study period.~* Any condition which, in the opinion of the investigator, renders the subject unfit for participation in the study.~* Child in care.~* Previous vaccination at any time with an H5N1 vaccine.~* Medical history of physician-confirmed infection with a H5N1 virus.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- GSK1562902A 6 to 12 M Group (Type: EXPERIMENTAL): Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
- GSK1562902A 12 to 24 M Group (Type: EXPERIMENTAL): Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
- GSK1562902A 24 to 36 M Group (Type: EXPERIMENTAL): Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete